For Healthcare Professionals Outside the US

INDICATION

PLUVICTO® in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated
for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)
who have been treated with AR pathway inhibition and taxane-based chemotherapy.1

Learn How PLUVICTO® Works

PLUVICTO® is a PSMA-targeted radioligand therapy (RLT) that delivers DNA-breaking
radiation directly to PSMA-positive bone, nodal, and visceral metastases.1-4

PLUVICTO® targets PSMA-positive cells, including prostate cancer cells.1

See how PLUVICTO® works.

Video thumbnail

View VISION TRIAL Data

The VISION trial was a phase 3 prospective, multicentre, randomized, active-controlled, open-label study.
The trial enrolled 831 men who had PSMA-positive mCRPC with e.g. bone and/or soft tissue disease and had previously
received at least 1 androgen-receptor pathway inhibitor (ARPI) and 1 or 2 taxane-based regimens.5

The trial compared treatment with PLUVICTO® (7.4 GBq (200 mCi) once every 6 weeks for 4 to 6 doses) + best standard of care (BSoC; i.e., physician’s choice of ARPI, androgen-reducing agents, bone-targeted agents, radiation therapy, glucocorticoids, or others) vs. treatment with BSoC alone.5,6

Video thumbnail
 
Learn more about PSMA PET imaging with LOCAMETZ®
Learn more
Locametz Logo
References:
  1. PLUVICTO®. Summary of Product Characteristics. 2022.
  2. Boyd M, et al. Gene Ther. 1999 Jun;6(6):1147-52.
  3. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2020;48(5):1339-1350.
  4. Fendler WP, et al. J Nucl Med. 2017;58(11):1786-1792.
  5. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103.
  6. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. Supplementary Appendix.

This is a promotional international website for PLUVICTO® and is intended for healthcare professionals outside the US only. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for country specific information.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)